← Back to Search
A Randomized Controlled Trial Of A Reduced Daily Dose Of Zidovudine In Patients With The Acquired Immunodeficiency Syndrome
M. Fischl, C. Parker, C. Pettinelli, M. Wulfsohn, M. Hirsch, A. Collier, D. Antoniskis, M. Ho, D. Richman, E. Fuchs, T. Merigan, R. Reichman, J. Gold, N. H. Steigbigel, G. Leoung, S. Rasheed, A. Tsiatis
Published 1990 · Medicine
Save to my Library
Download via 🐼 PaperPanda Download via oaDOI Download via OAB Download via LibKey Download via Google Google ScholarAnalyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Abstract Background. The initially tested dose of zidovudine for the treatment of patients with advanced disease caused by the human immunodeficiency virus type 1 (HIV) was 1500 mg. Although this dose is effective, it is associated with substantial toxicity. Methods. To evaluate the efficacy and safety of a reduced dose, we conducted a randomized controlled trial in 524 subjects who had had a first episode of Pneumocystis carinii pneumonia. The subjects were assigned to receive zidovudine in either a dose of 250 mg taken orally every four hours (the standard-treatment group, n = 262) or a dose of 200 mg taken orally every four hours for four weeks and thereafter 100 mg taken every four hours (the low-dose group, n = 262). Results. The median length of follow-up was 25.6 months. At 18 months the estimated survival rates were 52 percent for the standard-treatment group and 63 percent for the low-dose group (P = 0.012 by the log-rank test). At 24 months the estimated survival rates were 27 percent for the st...
This paper references
On a Test of Whether one of Two Random Variables is Stochastically Larger than the Other
H. B. Mann (1947)
Asymptotically Efficient Rank Invariant Test Procedures
R. Peto (1972)
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.
R. Peto (1977)
Statistical Methods for Rates and Proportions, 2nd ed
W. Grove (1981)
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.
H. Mitsuya (1985)
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.
M. Fischl (1987)
The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.
D. Richman (1987)
Human immunodeficiency virus (HIV) antigenemia (p24) in the acquired immunodeficiency syndrome (AIDS) and the effect of treatment with zidovudine (AZT).
G. G. Jackson (1988)
Long‐term administration of 3′‐Azido‐2′,3′‐dideoxythymidine to patients with AIDS‐related neurological disease
R. Yarchoan (1988)
Zidovudine treatment of patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex: St Stephen's Hospital experience.
D. Stambuk (1989)
Quantitation of human immunodeficiency virus type 1 in the blood of infected persons.
D. Ho (1989)
Clinical experience with zidovudine for patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex.
A. Pinching (1989)
The antiviral effect of zidovudine and ribavirin in clinical trials and the use of p24 antigen levels as a virologic marker.
S. Spector (1989)
Plasma viremia in human immunodeficiency virus infection.
R. Coombs (1989)
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.
B. Larder (1989)
Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group.
M. Fischl (1989)
Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus.
D. Richman (1990)
Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
P. Volberding (1990)
This paper is referenced by
“How Many Dead Hemophiliacs Do You Need?” And the Band Played on (1993)
M. S. Rosenthal (2020)
Pathogenesis, clinical course, and recent issues in HIV-1-infected Japanese hemophiliacs: a three-decade follow-up.
S. Oka (2020)
Applying phylogenetic lineage-level diversification rate to infer epidemiological risk factors and spatiotemporal distribution of HIV transmission in British Columbia
Angela McLaughlin (2019)
A Review of Clinical Pharmacokinetic and Pharmacodynamic Profiles of Select Antiretrovirals: Focus on Differences among Chinese Patients
Xiaoli Du (2019)
Nonparametric group sequential methods for evaluating survival benefit from multiple short-term follow-up windows.
M. Xia (2018)
Permeability and in vivo distribution of poly(Ɛ-caprolactone) nanoparticles loaded with zidovudine
Milena C. R. S. Magalhães (2018)
Observational Studies Analyzed Like Randomized Trials and Vice Versa
M. Hernán (2017)
Clinical Pharmacology of Antibiotics
M. Scheld (2016)
Dallas Buyers Club (2013): la investigación clínica con fármacos durante la epidemia del sida de los años 80
M. Farré (2015)
Prevalence of Anemia and Immunological Markers in HIV-Infected Patients on Highly Active Antiretroviral Therapy in Northeastern Nigeria
B. Denue (2013)
Effect of Aspergillus flavus on the Liver of Experimental Rats Administered with Antiretroviral Drugs
T. K. Udeani (2013)
New sustained release of Zidovudine Matrix tablets − cytotoxicity toward Caco-2 cells
J. V. Santos (2013)
Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients
E. Cohen (2012)
Highly active antiretroviral therapy (HAART) and testicular morphology: current status and a case for a stereologic approach.
O. O. Azu (2012)
Role of delay differential equations in modelling low level HIV viral load
Edgar McGuinness (2012)
Effekte eines aeroben Ausdauertrainings auf HIV-positive Patienten unter antiretroviraler Therapie
Alexander Antczack (2012)
Adverse Events in HIV- infected Children on Antiretroviral Therapy at a Teaching Hospital in Lagos, Nigeria: A Retrospective Study
K. Oshikoya (2012)
Antiviral Therapy in Human Immunodeficiency Virus Infection
E. Sandström (2012)
The Effects of Long Term Zidovudine Therapy and Pneumocystis carinii Prophylaxis on HIV Disease
D. Hoover (2012)
Parâmetros imunovirológicos em pacientes infectados pelo HIV, tratados ou não com antirretrovirais
K. I. Tasca (2012)
Early Versus Delayed Treatment of HIV Infection
D. Richman (2012)
Jan Sahai (2011)
zidovudine factor and erythropoietin decreases hematologic toxicity from Combined therapy with recombinant granulocyte colony-stimulating
Steven A. Miles (2011)
AIDS and HIV Infection
R. Rothman (2010)
The Essentiality of Nutritional Supplementation in HIV Infection and AIDS
R. Jariwalla (2010)
Efficacy and tolerability of zidovudine 200 mg twice a day as part of combination antiretroviral therapy for 96 weeks.
C. Duncombe (2010)
The development of combination therapies for HIV infection.
M. Delaney (2010)
Utvikling og effekt av antiretroviral behandling ved HIV/AIDS
Universitetet i Oslo (2009)
AVALIAÇÃO DO MODELO DE HAMSTER PARA DETECÇÃO DAS ALTERAÇÕES LIPÍDICAS E CARDIOTOXICIDADE ASSOCIADAS À TERAPIA CONTRA O VÍRUS DA IMUNODEFICIÊNCIA HUMANA
São Paulo. (2009)
In vivo-Analyse der hepatischen mitochondrialen Funktion HIV-infizierter Patienten durch den 13 C- Methionin-Atemtest
Ludwig-Maximilians-Universitaet Muenchen (2009)
HIV, antiretroviral therapy, and tuberculosis: Outcomes in Johannesburg, South Africa
D. Westreich (2008)
Causal Inference in Clinical Trials
L. Li (2008)See more